Epigenomics, Predictive Biosciences deal

Predictive Biosciences exercised a 2009 option to commercialize a prostate cancer test in the U.S. incorporating Epigenomics' glutathione S-transferase P1-1 (GST P1-1) DNA methylation biomarker. Epig...